

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

April 19, 2017

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for January 11, 2017 meeting
- IV. Secretary's report
- V. Old Business
 - A. MCO responses to Miralax[®] (Amerigroup/WellCare)
 - B. Protocols review and streamlining
 - C. Smoking cessation therapy processes report
 - D. Proposed educational newsletter: "Using Naloxone to Prevent Drug Overdose Deaths"
- VI. New Business
 - A. Proposed protocol for safe and efficient use of eteplirsen (Exondys 51[®])
 - B. Clarification of brand name prescription drug policy for behavior health patients
- VII. Informational Highlights/Reports
 - 1. Molina/NJ HMO 4th Quarter 2016 Prior Authorization Report
 - 2. Summary of DURB Action Items
 - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
(b) Physician-administered drugs by amount paid/category
 - 4. Medication information:
 - (a) New Jersey Enacts Strict Opioid Prescribing Law
 - (b) FDA approves first treatment for frequent urination at night due to overproduction of urine
 - (c) Georgia bill would hold providers criminally liable for not tracking opioid prescriptions
 - (d) Drug Overdose Deaths in the United States, 1999-2015
 - (e) Gouging the elderly: Number of US seniors on multiple psychotropic drugs doubles over decade